SomaLogic, Inc.

M&A

Financial Advisor, January 2024

SomaLogic, Inc.
Merger with Standard BioTools (Nasdaq: LAB)

SomaLogic is catalyzing drug research and development and biomarker identification as a global leader in proteomics technology. With a single 55 microliter plasma or serum sample, SomaLogic can run 7,000 protein measurements, covering more than a third of the approximately 20,000 proteins in the human body. For more than 20 years SomaLogic has supported pharmaceutical companies, and academic and contract research organizations who rely on the Company’s protein detection and analysis technologies to fuel drug, disease, and treatment discoveries in such areas as oncology, diabetes, and cardiovascular, liver and metabolic diseases.

More Like This

Jan 2024
$250 Million

Follow-on Offering

Bookrunner

View Details >
Jan 2024
$113 Million

Follow-on Offering

Bookrunner

View Details >
Jan 2024

Frontier Service Partners, a portfolio company of Imperial Capital, has been acquired by Apex Service Partners, a platform of Alpine Investors

Exclusive Financial Advisor

View Details >